title: Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients.
abstract: We investigated the effects of omega-3 fish oil (FO) supplementation on lipid metabolism, glycemic control, and blood pressure (BP) in patients with type II diabetes mellitus. In 22 diabetic patients without overt hyperlipidemia, serum triglyceride, total cholesterol, high density lipoprotein (HDL)-cholesterol, HDL2-cholesterol, HDL3-cholesterol, and apolipoprotein A-I (apo A-I) levels did not change during omega-3 FO supplementation for 8 weeks. The mean serum apo B concentration increased significantly [baseline, 2.56 +/- 0.11 (+/- SEM) mmol/L; 4 weeks, 2.82 +/- 0.13 mmol/L; 8 weeks, 2.80 +/- 0.13 mmol/L; P less than 0.01]. The mean plasma postheparin lipoprotein lipase activity increased transiently during the fourth week (baseline, 168 +/- 17 U/mL; 4 weeks, 182 +/- 18 U/mL; P less than 0.05), whereas postheparin hepatic triglyceride lipase activity did not change. Glycemic control worsened transiently during the fourth week, (baseline, 7.7 +/- 0.4%; 4 weeks, 8.4 +/- 0.3%; P less than 0.05). Both systolic and diastolic BP decreased significantly throughout the study (systolic BP: baseline, 142 +/- 5 mm Hg; 8 weeks, 128 +/- 5 mm Hg; diastolic BP: baseline, 88 +/- 4 mm Hg; 8 weeks, 80 +/- 3 mm Hg; P less than 0.01). These findings suggest that in type II diabetics without overt hyperlipidemia, omega-3 FO supplementation does not improve either the glycemic control or serum lipids, and it is associated with a potentially detrimental rise in serum apo B concentrations. Until more information is available, use of such supplementation should be discouraged.
authors: Department of Medicine, Wayen State University, Detroit, Michigan 48202.
authors: S E
authors: SE
authors: Kasim
authors: B
authors: B
authors: Stern
authors: S
authors: S
authors: Khilnani
authors: P
authors: P
authors: McLin
authors: S
authors: S
authors: Baciorowski
authors: K L
authors: KL
authors: Jen
mesh_terms: D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects*; D002214:Capsules; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003927:Diet, Diabetic; D004341:Drug Evaluation; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008066:Lipolysis; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D002214:Capsules; D005231:Fatty Acids, Unsaturated; D005395:Fish Oils; D008055:Lipids; D008074:Lipoproteins